Leerink Partners analyst Andrew Berens raised the price target on Seattle Genetics (NASDAQ: SGEN) to $105.00 (from $101.00) while maintaining a Outperform rating.

Berens is raising Adcetris estimates on unanticsurvival surviable benefit.